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Cardioviruses cause serious disease, mainly in ro-
dents, including diabetes, myocarditis, encephalomyelitis, 
and multiple sclerosis–like disseminated encephalomyeli-
tis. Recently, a human virus isolate obtained 25 years ago, 
termed Saffold virus, was sequenced and classiﬁ  ed as a 
cardiovirus. We conducted systematic molecular screen-
ing for Saffold-like viruses in 844 fecal samples from pa-
tients with gastroenteritis from Germany and Brazil, across 
all age groups. Six cardioviruses were identiﬁ  ed in patients 
<6 years of age. Viral loads were 283,305–5,044,412,175 
copies/g of stool. Co-infections occurred in 4 of 6 children. 
No evidence for outbreak-like epidemic patterns was found. 
Phylogenetic analysis identiﬁ  ed 3 distinct genetic lineages. 
Viral protein 1 amino acids were 67.9%–77.7% identical 
and had a distance of at least 39.4% from known cardio-
viruses. Because closely related strains were found on 2 
continents, global distribution in humans is suspected. Saf-
fold-like viruses may be the ﬁ  rst human cardiovirus species 
to be identiﬁ  ed.
T
he family Picornaviridae comprises 9 genera with 
>142 species and 200 serotypes, many of which are 
highly pathogenic for humans and animals. The genus Car-
diovirus contains 2 animal-pathogenic species— Encepha-
lomyocarditis virus and Theilovirus—that occur mainly in 
rodents and swine. The type species is Encephalomyocardi-
tis virus, which includes strains of murine encephalomyo-
carditis virus (EMCV), Mengo virus, and Maus Eberfeld 
virus. The species Theilovirus is represented by Theiler’s 
murine encephalomyelitis virus (TMEV, also known as 
mouse poliovirus) and rat encephalomyelitis virus. Both 
species show clinical association with encephalomyelitis 
in mice, and EMCV shows an additional association with 
myocarditis (1). EMCV is used in laboratory mice to model 
the symptoms and pathogenesis of human type I diabetes 
and viral myocarditis (2,3). TMEV comprises strains of 
differing neuropathogenicity, which constitute accepted 
mouse models of either human acute poliomyelitis or dis-
seminated encephalomyelitis. The latter is indistinguish-
able from multiple sclerosis in humans (4,5).
No human-pathogenic cardiovirus is recognized today. 
Isolation of EMCV-like viruses from mammals other than 
rodents and pigs has been reported in the past (6–9), but 
the clinical relevance of these sporadic ﬁ  ndings has been 
doubted, especially ﬁ   ndings involving humans. TMEV-
like cardiovirus may have been involved in an apparently 
infectious neurodegenerative disease in persons living in 
Vilyuisk, Siberia (10). A virus related to TMEV, named Vi-
lyuisk virus, was isolated from a laboratory mouse that had 
been injected intracerebrally with blood and cerebrospinal 
ﬂ  uid (CSF) of a symptomatic patient (11,12). However, se-
rum antibodies to Vilyuisk virus were found only in some 
but not all Vilyuisk encephalitis patients by a mouse neu-
tralization assay (13–15). Therefore, controversy remains 
on whether the virus really circulates in humans or whether 
the isolate may have resulted from mouse passage.
Recently, the genome of another cardiovirus, the Saf-
fold virus, was characterized (16). This virus was isolated 
in 1982 from a stool sample of a child with fever of un-
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known origin. No mouse passage was involved, but the 
original stool sample had been passaged several times in 
Wistar Institute–38, human fetal diploid lung–645, and 
human fetal diploid kidney cells. No associated study has 
been conducted to determine whether this singular cell cul-
ture isolate had any clinical meaning. Most recently, Abed 
and Boivin reported that a cardiovirus similar to Saffold 
virus was identiﬁ  ed from a cell culture showing cytopathic 
effects but reacting only weakly with antienterovirus se-
rum pools (17). Speciﬁ  c screening identiﬁ  ed the same or 
a closely related virus from >2 cell cultures. All cultures 
had been injected with respiratory secretions from children 
with respiratory disease. The report summarized 3 clinical 
cases but did not address prevalence, disease association, 
or molecular–epidemiologic aspects of the virus.
In this study, we used broad-range nested reverse tran-
scription–PCR (RT-PCR) targeted at domains conserved 
between the Saffold prototype virus, various TMEV strains, 
and EMCV. We screened 844 patients from all age groups 
with acute enteritis, including 39 controls, in 3 independent 
cohorts from 2 countries (Germany and Brazil) on 2 con-
tinents. Viral loads were determined by speciﬁ  c real-time 
RT-PCR. Phylogenetic analysis showed 3 independent 
lineages of circulating Saffold-like viruses (SafVs). Analy-
sis of amino acid identities and considerations regarding 
transmission patterns suggest that SafV most likely con-
stitutes a new cardiovirus that is associated with humans 
worldwide.
Materials and Methods
Patients and Samples
Cohort 1 
From January through December 2004, 538 stool sam-
ples were collected from patients in urban areas in north-
ern Germany in a prospective study on acute, community-
acquired diarrhea. All patients were outpatients who had 
been examined by general practitioners; 96 (17.8%) were 
<6 years old. Diarrhea in these patients was deﬁ  ned as ex-
cretion of at least 2 loose and malodorous stools during 24 
hours for breastfed infants and of at least 2 loose stools 
in a 24-hour period for all other patients. Patients were 
excluded if they had inﬂ  ammatory bowel disease, celiac 
disease, cystic ﬁ  brosis, food intolerance, or a known ma-
lignant disease. The cohort included stool samples from 39 
control patients of compatible ages with conditions other 
than enteritis. Written informed consent was obtained from 
all patients or their parents. The study protocol and data 
handling were approved by the local ethics committee. In 
both groups, patients with norovirus, adenovirus, enterovi-
rus, astrovirus, or rotavirus infection were excluded.
Cohort 2
Archived stool samples from 118 patients with acute 
enteritis were obtained from the routine diagnostic labora-
tory of a municipal health service in Hamburg, Germany. 
This cohort contained 3 subcohorts classiﬁ  ed with regard 
to patient age and context of sampling: 1) children sampled 
during childcare center outbreaks (n = 51); 2) adults sam-
pled in the context of outbreaks of gastroenteritis mainly in 
association with catering and canteen food (n = 35); and 3) 
senior citizens sampled because of outbreaks of enteritis in 
retirement homes (n = 32).
Cohort 3 
This cohort contained 188 samples from infants and 
children in Brazil with acute diarrhea, deﬁ  ned as >3 wa-
tery stools in the previous 24 hours and within 13 days be-
fore admission. Patients were seen as outpatients or were 
hospitalized because of severe dehydration from February 
through December 2006 at the University Hospital Profes-
sor Edgar Santos in Salvador de Bahia, Brazil. Informed 
consent was obtained from the mothers of all patients en-
rolled in the study. The study was approved by the institu-
tional ethics committee. All analyses were performed at the 
Infectious Disease Research Laboratory, University Hospi-
tal Professor Edgar Santos.
Co-infection in the Brazil cohort was assessed by us-
ing recently published methods of real-time RT-PCR for 
norovirus, rotavirus, enterovirus, parechovirus, adenovirus, 
and astrovirus (18–23). For the Germany cohorts, testing 
was done with the IDEIA rotavirus, adenovirus, and astro-
virus antigen enzyme immunoassays (DakoCytomation, 
Ely, UK) and nested RT-PCRs as described before (23). 
All samples had been stored at –20°C and thawed a few 
times before this study.
Preparation of Stool Samples for RT-PCR
Stool samples stored at –20°C were extracted by us-
ing the QIAamp DNA Mini Stool Kit or the QIAamp Viral 
RNA Mini Kit (QIAGEN, Hilden, Germany). Both proto-
cols used an input of ≈200 mg of stool prediluted 1:10 in 
phosphate-buffered saline. Suspensions were vortexed and 
centrifuged, and 200 or 140 μL of supernatant, respective-
ly, was extracted according to the manufacturer’s instruc-
tions.
Nested RT-PCR for Cardiovirus Screening
Primers (Table 1) were designed upon aligning the 
Saffold virus (GenBank accession no. EF165067) (16) 
with genomes of EMCV and TMEV strains. Saffold vi-
rus served as the template sequence. Formulations of both 
rounds of ampliﬁ  cation are shown in Table 1. Although the 
ﬁ  rst round alone was sufﬁ  cient for ampliﬁ  cation of an 800-
bp fragment in samples with an apparently high viral load, 
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only the nested protocol was able to amplify all samples 
with lower viral load and possible PCR inhibition (500-bp 
fragment).
SafV Real-time Quantitative RT-PCR Assay
Various combinations of primers and probes were 
designed manually upon inspection of the SafV prototype 
sequence EF165067 (16) and the newly sequenced SafV 
isolates from this study. Optimal primer and probe com-
binations and reaction conditions were determined experi-
mentally. The ﬁ  nal formulation is shown in Table 1. For the 
calculation of absolute virus RNA concentrations in stool 
samples, efﬁ  ciencies of RNA recovery for both RNA puri-
ﬁ  cation kits were evaluated by spiking known amounts of 
RNA in vitro transcripts into different cardiovirus-negative 
stool samples and comparing the quantiﬁ  cation results with 
those obtained from direct usage of the unextracted in vitro 
transcripts. Correction factors were 1/5 for the Viral RNA 
kit (i.e., 20% RNA recovery) and 1/250 for the DNA stool 
kit, indicating poor RNA recovery with the latter. The pro-
jected equivalent amount of stool tested per PCR vial, re-
ceiving 3 μL of RNA eluate, was 0.3 mg or 0.3 μL (see 
description of nucleic acid extraction).
P1 Gene Ampliﬁ  cation and Sequencing
Based on the published genome of Saffold virus 
EF165067 and the 5′ untranslated region sequences ob-
tained from our positive samples (nested PCR), primers 
spanning the complete viral protein 1 (VP1) gene were de-
signed. cDNA was produced by using the Superscript III 
Kit (Invitrogen, Karlsruhe, Germany) and an ≈4-kb frag-
ment was ampliﬁ  ed by using the Expand High Fidelity Plus 
Kit (Roche, Penzberg, Germany). This PCR product was 
sequenced directly from both sides by using primer walk-
ing. All primer sequences are available upon request.
In Vitro Transcribed RNA Standard
The 800-bp 5′-noncoding region fragment from sam-
ple BR/118/2006 was ligated into pCR 2.1 (Invitrogen) 
and TOPO-cloned. Plasmids were puriﬁ  ed, sequenced, and 
reampliﬁ  ed with plasmid-speciﬁ  c primers. Reampliﬁ  cation 
products were transcribed into RNA with a MegaScript T7 
kit (Ambion, Austin, TX, USA). After DNase I digestion, 
RNA transcripts were puriﬁ  ed with QIAGEN RNeasy col-
umns and quantiﬁ  ed photometrically. Sensitivity of real-
time RT-PCR was determined to be in the single-copy 
range when puriﬁ  ed and quantiﬁ  ed in vitro transcripts were 
ampliﬁ  ed.
Cardiovirus Strains and Accession Numbers
The following sequences were used for analysis and 
primer design: Saffold virus (EF165067), TMEV strain DA 
(M20301), TMEV strain GDVII (M20562), TMEV strain 
BeAn (M16020), Vilyuisk virus (M94868), Theiler-like vi-
rus of rats NGS910 (AB090161), Mengo virus (L22089), 
and EMCV (X87335). Several other subgenomic sequenc-
es of TMEV and EMCV were added in alignments for PCR 
primer design. At the time of preparation of this article, 
the polyprotein sequence of a Canadian virus isolate related 
to Saffold virus was described, AM922293 (17). This se-
quence was added to the phylogenetic analyses. The com-
plete P1 sequences from 4 of the SafVs identiﬁ  ed in this 
study could be determined and are available at GenBank 
under accession nos. EU681176–EU681179.
Virus Isolation
Virus-positive samples from Germany were subjected 
to virus isolation on a range of cell cultures as described 
earlier (23). However, no virus isolates were obtained. It 
was suspected that the stored samples had been frozen and 
thawed too many times because isolation of co-detected ad-
enoviruses and enterovirus was also unsuccessful.
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Table 1. PCR oligonucleotides and formulations for cardiovirus screening*  
ID no.  Sequence (5ƍ ĺ 3ƍ) Position†  Orientation  Usage 
CF188  CTAATCAGAGGAAAGTCAGCAT  188–209  +  Nested RT-PCR, 1st round‡ 
CF204  CAGCATTTTCCGGCCCAGGCTAA  204–226  +  Nested RT-PCR, 2nd round§ 
CR718  GCTATTGTGAGGTCGCTACAGCTGT  718–742  –  Nested RT-PCR, 2nd round§ 
CR990  GACCACTTGGTTTGGAGAAGCT  990–1011  –  Nested RT-PCR, 1st round‡ 
CF723 TGTAGCGACCTCACAGTAGCA 723–743  + Real-time  PCR¶ 
CR888 CAGGACATTCTTGGCTTCTCTA 888–909  –  Real-time  PCR¶ 
CP797  FAM-AGATCCACTGCTGTGAGCGGTGCAA-BHQ1  797–821  + (probe)  Real-time PCR¶ 
*ID, identification; RT-PCR, reverse transcription–PCR; FAM, 6-carboxyfluorescein; BHQ1, black hole quencher 1. 
†Relative to Saffold virus EF165067 genome. 
‡25-μL reactions used the QIAGEN OneStep RT-PCR kit (QIAGEN, Hilden, Germany), with 400 nmol/L each of 1st-round primers CF188 and CR990, 1 
μL enzyme mix, 1 μg bovine serum albumin, and 5 μL RNA extract. Amplification involved 30 min at 50°C; 15 min at 95°C; 10 cycles of 20 s at 94°C, 30 s 
starting at 60°C with a decrease of 1°C per cycle, and 50 s at 72°C; and 40 cycles of 20 s at 95°C, 30 s at 54°C, and 50 s at 72°C with a final elongation 
step of 5 min at 72°C. 
§50-μL reactions used 1 μL of 1st-round PCR product, with 1x Platinum Taq buffer (Invitrogen, Karlsruhe, Germany), 200 μmol/L deoxynucleoside 
triphosphates each, 2.5 mmol/L MgCl2, 400 nmol/L each of 2nd-round primers CF204 and CR718, and 1 U Platinum Taq polymerase. Amplification 
involved 3 min at 94°C and 45 cycles of 20 s at 94°C, 30 s at 60°C, and 40 s at 72°C. 
¶25-μL reactions used 3 μL of RNA extract, 1x reaction buffer and enzymes from the QIAGEN OneStep RT-PCR kit, 600 nM of primer CF723, 400 nM of 
primer CR888, and 160 nM of probe CP797. Cycling in an Applied Biosystems 7700 SDS instrument involved the following steps: 55°C for 15 min, 95°C 
for 15 min, and 45 cycles of 95°C for 15 s/58°C for 30 s. Human Saffold Virus Circulation
Results
A nested RT-PCR was designed on the basis of a re-
cently published sequence of a prototype human cardio-
virus, the Saffold virus. The 5′-noncoding region of this 
sequence was aligned with that of other cardioviruses, in-
cluding TMEV, EMCV, and Mengo virus. Primers were 
placed in regions conserved among the original Saffold vi-
rus sequence and various theiloviruses (Figure 1). Because 
several members of the Picornaviridae family are transmit-
ted by the fecal–oral route, the search for human cardiovi-
ruses was focused on patients with gastroenteritis. Samples 
from pretested cohorts of patients from 2 continents were 
examined (Table 2).
In the ﬁ  rst cohort, 538 stool samples were tested from 
538 outpatients of all ages who had acute enteritis in ab-
sence of common enteric virus infections. Stool samples 
from 39 asymptomatic patients served as controls. All pa-
tients were observed by practitioners in northern Germany 
and were not selected for an association with outbreaks of 
gastroenteritis. Samples from neither patients nor controls 
yielded virus. A second cohort from Germany comprised 
118 patients from all age groups sampled in the context of 
outbreak investigations by a municipal health center (Ta-
ble 2). Samples from 4 children yielded cardioviruses in a 
subcohort of 51 children from childcare centers. No virus 
was found in subcohorts of 35 adults sampled because of 
catering kitchen outbreaks, and 32 patients from retirement 
homes, respectively. In the third cohort, 188 children (1–60 
months of age) from an outpatient clinic in Salvador de Ba-
hia, Brazil, were examined; 2 (1.1%) and had positive test 
results for a cardiovirus.
All patients with positive results for cardiovirus were 
retested by a quantitative real-time RT-PCR for SafV, 
which was designed after sequencing of the 5′-noncoding 
regions of all viruses. Clinical information and the result-
ing viral load data are summarized in Table 3. All cases 
occurred in children <6 years of age who had symptoms 
of gastroenteritis. Both cases in Brazil occurred during the 
rainy season, when rainfull was frequent and temperatures 
were 20°–26°C. All case-patients in Germany were seen in 
November, when temperatures were ≈5°C and rainfall was 
frequent.
A broad range of viral loads was observed (283,305-
673,009,359 copies/mL or gram of stool). Co-infections 
with enteric viruses occurred in both patients from Brazil 
and in 2 of the 4 patients from Germany. Average viral 
loads in patients with and without co-infections were 1.7 × 
108 and 2.5 × 109 per mL or gram of stool, respectively. The 
difference was not signiﬁ  cant at the 95% conﬁ  dence level 
(1-way analysis of variance, p = 0.19).
Only 1 child had concomitant respiratory symptoms. A 
nasopharyngeal aspirate from this child taken at the same 
time as the positive stool specimen was tested by real-time 
RT-PCR for SafV; results were negative.
To appreciate the genetic range of cardioviruses in our 
patients, we ﬁ  rst sequenced an 800-bp fragment containing 
80% of the viral 5′-noncoding region from all 6 samples. 
The complete P1 gene could then be sequenced from 4 
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Figure 1. Nucleic acid alignment of the hybridization sites of diagnostic reverse transcription–PCR oligonucleotides. Oligonucleotides are 
shown below the alignment panel. The base count in the top line is based on Saffold virus, which also serves as the comparison sequence 
in the alignment. Dots represent identical bases in compared sequences; deviations are spelled out. A slash (/) represents a gap in the 
alignment; (rc) means that the reverse complementary sequence is shown for the antisense primer.
Table 2. Characteristics of samples obtained from gastroenteritis patients, 2004 and 2006 
Location Origin of samples  Patient age range  No. patients  Cardiovirus prevalence, % 
Brazil Hospital outpatient department  1–60 mo  188 1.1
Germany General  practitioners 1–98 y 538* –
Kindergartens 1–144 mo 51 7.8
Catering kitchens 16–65 y 35 –
Retirement homes 74–98 y 32 –
*This cohort contained no patients with predetected enteric viruses (refer to Materials and Methods section); 39 healthy controls were included. RESEARCH
samples. Samples D/PN11/2004 and BR/176/2006, which 
showed the lowest virus concentrations, did not yield P1 
gene PCR products on several trials.
In addition to the lineage containing the prototype Saf-
fold virus (hereafter referred to as the Saf-1 lineage), >2 ge-
netic lineages were identiﬁ  ed (Figure 2). A second lineage 
(Saf-2 lineage) comprised the strain from Germany, D/
VI2229/2004, the strain from Brazil, BR/118/2006, and the 
isolate from Canada, AM922293. A third lineage (Saf-3) 
was clearly differentiated from Saf-1 and Saf-2. It com-
prised the viruses D/VI2223/2004, D/VI2273/2004, and D/
PN11/2004, although the last viruscould be sequenced only 
in the 5′-noncoding region (the tree for the 5′-noncoding 
region is not shown because it provides little additional in-
formation for virus classiﬁ  cation).
In several genera of Picornaviridae, the degree of nu-
cleotide and amino acid identity in the P1 protein gene or 
in VP1 alone is used as a criterion of taxonomic classiﬁ  ca-
tion. Table 4 shows amino acid identities of strains of SafV, 
theilovirus, and EMCV in VP1. The degree of identity be-
tween theilovirus and EMCV was the same as that between 
encephalomyocarditis virus and SafV, ≈50%. The lowest 
degree of identity was seen between Saf-3 and EMCV at 
46.7%. The maximum degree of identity between strains 
of theilovirus and SafV was up to 60.6%. Within the 2 es-
tablished cardiovirus species, the lowest degree of identity 
between strains was observed between Vilyuisk virus and 
Theiler-like virus of rats, at 69.6%. The lowest degree of 
identity between SafV strains was 67.9%, as observed be-
tween both representatives of Saf-3 and the original Saffold 
virus (Saf-1). Lineages Saf-1 and Saf-2 were 77.3%–77.7% 
identical in their P1 protein genes.
Discussion
In parallel with a recent report on the detection of 
SafV cardioviruses in 3 children (17), we investigated in 
this study the prevalence of these agents in deﬁ  ned patient 
cohorts. We gained evidence that cardioviruses circulate in 
the human population and that they are genetically diver-
siﬁ  ed at a level similar to recognized cardiovirus species. 
They can be subdivided in 3 types and may constitute a 
novel cardiovirus species.
On the basis of the initial isolation of the prototype 
Saffold virus (16) from fecal material, we analyzed 844 
stool samples from Brazil and Germany by broad-range 
nested RT-PCR. Cumulative prevalence in all age groups 
was 0.71%. However, both in Germany and Brazil no virus 
was detected in patients >6 years of age. Virus prevalence 
in all children up to 6 years was 1.84%. This age spectrum 
was in concordance with the 4 case-patients reported in ear-
lier studies, who were 8 months, 19 months, 23 months, 
and 4 years old (16,17).
This age distribution is consistent with epidemiologic 
patterns seen for other picornaviruses that have comparably 
low antigenic variability and high attack rates, e.g., certain 
enteroviruses and human parechoviruses (25,26). These vi-
ruses infect a large part of the young human population and 
rarely infect adults. Adaptive immunity rather than condi-
tions of exposure (sanitation, food safety) likely determines 
probability of infection, making exposure conditions less 
relevant in outbreak settings (23). Consistently, we did not 
observe a different prevalence between Germany and Bra-
zil (where hygienic conditions and food safety are suppos-
edly inferior). Moreover, even though all 4 viruses from 
Germany were obtained from samples taken within a 10-
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Table 3. Characteristics of cardiovirus-positive patients, Germany and Brazil, 2004 and 2006* 
Patient ID 
Sampling
date
Sampling site 
epidemiologic context
Patient
sex 
Patient age 
at sampling  Clinical symptoms
Viral co-
infections†
Virus
concentration‡
BR/118/2006 2006 Aug 2  Salvador, Brazil  M 6 wk  Gastroenteritis  Adenovirus,
norovirus
33,373,329
BR/176/2006 2006 Oct 2  Salvador, Brazil  F 4 y  Gastroenteritis, 
URTI§
Norovirus 283,305
D/VI2273/2004  2004 Nov 9  Outbreak, childcare 
center, Altona, 
Hamburg
Germany 
M 2 y  Gastroenteritis  Adenovirus 673,009,359
D/VI2223/2004  2004 Nov 2  Single case, pediatric 
outpatient, Hamburg 
Germany 
M 2 y  Gastroenteritis  None 59,687,364
D/VI2229/2004  2004 Nov 1  Single case, 
kindergarten,
Bergedorf, Hamburg 
Germany 
F 4 y  Gastroenteritis  None 5,044,412,175
D/PN11/2004 2004 Nov 15  Family outbreak, 
Bergedorf, Hamburg 
Germany 
M 6 y  Gastroenteritis  Enterovirus 3,093,024
*ID, identification; URTI, upper respiratory tract infection. 
†All samples were tested for norovirus, rotavirus, adenovirus, astrovirus, parechovirus, and enterovirus. 
‡Viral RNA copies in |1 g/1 mL of stool. 
§Respiratory tract sample testing negative for Saffold-like virus. Human Saffold Virus Circulation
day period in a single city, they were clearly distinct from 
each other and belonged to different genetic lineages. Thus, 
no evidence of outbreak-like transmission was found. All 
viruses in our study were isolated from samples obtained 
in the cold or rainy season, when low UV irradiation and 
the crowding of persons favor virus transmission. This sup-
ports the notion that transmission of SafV from person to 
person may be more relevant than transmission through 
food or water.
Stool samples of 4 of 6 children with SafV showed at 
least 1 viral co-infection with typical enteric viruses, in-
dicating that SafV may not have been the only cause of 
the observed gastroenteritis. This conclusion is also sup-
ported by the fact that patients with single infection had 
no higher viral loads than patients with co-infection. It re-
mains to be determined whether the enteric tract might be 
more important for replication and shedding of virus than 
for primary pathogenesis; at least for now, any such con-
clusion would be premature. Nonetheless, the high viral 
load observed in stool samples of our patients suggests a 
role of the fecal–oral route for transmission. Further stud-
ies are clearly needed to investigate disease association of 
SafV. Such studies would greatly beneﬁ  t from the inclusion 
of a control group without clinical symptoms of diarrhea, 
and, if possible, of greater size than the group included in 
our study. Moreover, studies on virus prevalence should be 
complemented by serologic surveys that use neutralization 
tests, as soon as these become available.
Notably, in 3 cases reported recently from Canada, vi-
rus was isolated from respiratory specimens from children 
with respiratory symptoms (17). In our study, only 1of 6 
patients exhibited symptoms of upper respiratory tract in-
fection, and no cardiovirus could be detected by PCR from 
nasal secretions. Future studies should address systemati-
cally whether SafV is associated with respiratory disease.
The molecular ecology of SafV seems especially rel-
evant in view of the diversiﬁ  ed and strain-dependent patho-
genetic changes caused by the related TMEV in rodents. 
Neurovirulent strains, such as GDVII, cause an acute en-
cephalomyelitis in mice, resulting in a high proportion of 
deaths. Persistent strains like BeAn and DA cause a chronic 
demyelinating disease that provides an experimental animal 
model for multiple sclerosis in humans (4,27–30). These 
drastically different disease patterns seem to be determined 
by conformational changes in the outermost structures of 
VP1 and VP2 (31). Even minimal genetic alterations may af-
fect disease attenuation (30,32,33). Analyzing the genetic di-
versity of cardioviruses in humans appears highly relevant.
Our study shows that 3 different genetic lineages of 
SafV are circulating, which suggests nonrecent virus di-
versiﬁ  cation in humans. These ﬁ  ndings indicate that a true 
virus–host relationship exists, rather than sporadic or ac-
cidental spillover of a virus that resides in another animal 
(as observed with EMCV in humans; 8). Support of a genu-
ine human association is also provided by the occurrence 
of closely related members of the same lineage (Saf-2) in 
Brazil and in Germany. Such wide distribution requires ef-
ﬁ  cient transmission of virus from human to human. In com-
bination with ﬁ  ndings of the virus in the United States (16) 
and Canada (17), a proposal that the distribution of SafV is 
global seems reasonable.
The level of diversiﬁ  cation between SafV genetic lin-
eages is clearly higher than the 20% amino acid distance 
in the VP1 protein, which resembles the distance between 
serotypes of enteroviruses or types of human parechovirus-
es (1,34,35). In analogy with human parechoviruses, one 
could thus look at the SafV lineages deﬁ  ned in this study as 
types (SafV-1 to 3 in analogy to human parechovirus types 
1 to 6). We suspect that these types may also be discrimi-
nated by differential cross-neutralization properties as soon 
as neutralization tests become available. Types could then 
be redeﬁ  ned to serotypes.
The amino acid distance between isolates from the 2 es-
tablished cardiovirus species, Encephalomyocarditis virus 
and Theilovirus, was ≈50%, whereas the distance between 
theilovirus and SafV isolates was 40%. However, genetic 
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Figure 2. Phylogenetic relationships in the P1 and viral protein 1 
(VP1) genes. Analysis was done by using a neighbor-joining method 
with pairwise deletion for gaps, and 1,000 bootstrap reiterations for 
conﬁ  dence testing. Bootstrap conﬁ  dence values are depicted next 
to root points. Branch lengths are proportional to the evolutionary 
distances used to infer the phylogenetic tree. Phylogenetic analyses 
were conducted by using MEGA version 4 (24). For cardiovirus 
isolates from GenBank, accession number is shown after isolate 
identiﬁ  cation number. For economic reasons, only for VP1 is the 
whole cardiovirus genus depicted. New strains from this study are 
shown in boldface. TMEV, Theiler murine encephalomyelitis virus; 
EMCV, murine encephalomyocarditis virus. Scale bars indicate 
number of substitutions per site.RESEARCH
distance is not the only criterion for classifying cardiovirus 
species. The clear subdivision into types and, most criti-
cally, the likely association with a different host (human 
instead of rodent), makes it appear not unlikely that SafV 
may be classiﬁ  ed as a new cardiovirus species in the future. 
However, more genetic, ecologic, and functional analysis 
must be done before such a conclusion can be reached.
In recent years, several novel viruses have been dis-
covered in humans, mostly by advanced molecular screen-
ing (36–38). Despite intensive clinical study, some of these 
viruses still cannot be associated with clinically relevant 
disease. Our study shows that SafV is circulating in hu-
mans, but we cannot prove any clinical relevance from our 
data. However, 2 facts suggest that it may be rewarding to 
look for SafV disease associations in speciﬁ  cally selected 
cohorts of patients. First, 2 groups independently have 
isolated the virus on cell cultures, which suggests that the 
agent may replicate in a range of human tissues (16,17). 
Notably, most recently identiﬁ  ed viruses that show no overt 
disease association do not grow in culture (36–38). Second, 
the murine cardioviruses, and especially TMEV, the closest 
relative to SafV, display a range of clinical associations that 
are dependent on strain properties (4,27–30). The existence 
of high and low pathogenic variants most likely provides 
advantages in the interplay between host population den-
sity, herd immunity, and viral replicative ﬁ  tness. The over-
all genetic range of SafV observed in this preliminary ge-
netic characterization seems to exceed that of both species, 
Theilovirus and Encephalomyocarditis virus. Research into 
the human disease association of SafV should therefore re-
ceive high priority in the clinical virology community.
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